Previous studies have implicated emerging pathways in HCC, such as HGF/MET, Wnt/β-catenin, and VEGF/VEGFR; these pathways could serve as novel molecular targets for developing anti-HCC therapies [3–5]. This evidence concerns the gene MET and hepatocellular carcinoma.